TrialFrontiers in pharmacology2026

Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial.

Yuzhou Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.